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 Abstract    
Objectives: Infections with human papillomavirus (HPV) are sexually transmitted. Their prevalence in males is 
comparable to females, but  infection in men is largely unknown. Since such information is needed to establish 
prevention strategies, the goal of our study was to estimate the incidence of type-specific genital HPV infection 
among men in Poland.
Material and Methods: Within a multi-center clinical preventive trial, penile sampling of 826 (100%) uncircumcised 
and sexually active males (aged 25–69 yrs.) was studied. Peniscopy was performed in addition to routine clinical 
examination.  DNA HPV in smears was detected by hybrid capture (HC2) and in the biopsy material by means of 
polymerase chain reaction (PCR).
Results: Twenty-three HPV types were detected, including 11 high-risk oncogenic (53–6.4% men) and in 65 
(7.87%) individuals both oncogenic and nononcogenic simultaneously – altogether 118 (14.3%) and also 12 low-
risk multiple nononcogenic types (248-30% men). Penile HPV prevalence was approximately 26.8%. In 53 (6.4%) 
cases we detected multiple oncogenic types (single HPV16 in only 17 cases – 2.1%). Penile HPV DNA was 
detection did not appear to be associated with age. 
Our analyses also suggested a lower prevalence of HPV infection among male participants who reported consistent 
condom use and fewer sexual partners. In men with history of having more than 10 sexual partners over their 
lifetime increased the likelihood of detecting HPV DNA.
Conclusions: Data from our study showing a high prevalence of HPV infection in the Polish population of men will 
be helpful for future studies on HPV transmission dynamics. 
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Background
Genital	 human	 papillomavirus	 (HPV)	 infections	 may	
be	 connected	 with	 the	 development	 of	 carcinomas	 and	
other	 dermoepithelial	 changes	 (intraepithelial	 neoplasia).	
Multidirectional	 studies	 showed	 that	 chronic	 HPV	 infection	
is	 a	 necessary,	 but	 not	 sufficient	 factor	 for	 the	 development	
of	 cervical	 cancer	 [1].	The	 presence	 of	HPV	 infection	 in	men	
is	 largely	unknown.	Although	men	are	 regarded	as	a	dominant	
factor	 in	 infection	 transmission	 to	 their	 female	 sexual	 partners	
they	 do	 not	 develop	 clinically	 significant	 HPV-related	 lesions	
very	often	and	are	usually	asymptomatic	during	relatively	short	
lasting	infections	[2].	Little	 is	known	about	multiple-type	HPV	
prevalence	 and	 associated	 factors	 such	 as	 anal	 intraepithelial	
neoplasia	and	anal	cancer	in	men,	but	probably	the	most	common	
type	is	HPV16	[3].	The	frequency	of	HPV	infections	is	lower	in	
males	than	in	females,	a	finding	which	may	be	due	to	the	lower	
incidence	and	shorter	duration	of	 infection	as	well	as	 technical	
difficulties	 in	 selecting	 appropriate	 sites	 for	 cellular	 material	
sampling	for	molecular	studies	in	males	[4].
HPV	 genital	 infections	 in	 men	 can	 manifest	 in	 various	
clinical	 forms	 –	 from	 asymptomatic	 infection	 to	 squamous	
carcinomas.	Most	frequently	the	lesions	present	as	genital	warts,	
which	are	predominantly	located	at	the	distal	parts	of	penis	and	
are	 caused	 by	 low	 oncogenic	 risk	 HPV	 types	 –	 6	 and	 11	 [5].	
Persistent	 infections	 with	 high-risk	 HPV	 types	 16	 and	 18	 are	
associated	with	development	of	nearly	50%	of	squamous	penile	
cancer	cases	[6].
In	 Poland	 and	 worldwide,	 HPV	 infection	 poses	 a	 major	
problem	 for	 the	 healthcare	 industry	 since	 the	 lack	 of	 evident	
signs	of	 infection	 in	men	cause	 the	unknowing	transmission	of	
the	virus	to	females	in	whom	cervical	cancer	is	prone	to	develop.	
The	goal	of	our	study	was	to	estimate	the	incidence	and	number	
of	 type-specific	 genital	HPV	 infection	 in	men	 and	 identify	 the	
associated	factors	among	patients	in	Poland.		
Method
This	 multi-center	 clinical	 preventive	 trial	 studied	 820	
(100%)	 sexually	 active,	 HIV-seronegative,	 and	 uncircumcised	
patients	 (aged	 19-80	 yrs.)	 residing	 in	 Poland.	 Despite	 routine	
clinical	 examination,	 visual	 examination	 of	 the	 external	
genitalia,	 including	 the	 shaft	 of	 penis,	 prepuce,	 glans,	 corona,	
urethral	meatus,	navicular	fossa	and	skin	of	the	scrotum,	as	well	
as	peniscopy	to	visualize	 the	perineum	were	also	performed.	A	
cytologic	smear	was	obtained	from	the	urethra	using	cytobrash,	
and	 5%	 acetic	 acid	 was	 applied	 to	 the	 aceto-white	 areas.	
HPV	 DNA	 was	 detected	 in	 the	 biopsy	 material	 by	 means	 of	
polymerase	 chain	 reaction	 (PCR)	 as	 described	 previously	 in	
other	publications	[8].	Five	patient	groups	were	created	based	on	
their	reason	for	consultation	and	two	groups	based	on	percentile	
values	of	age.	The	age	groups	were:	I	–	19-33	years	old	(436	pts.	
–	54.2%),	II	–	34-70	(368	pts.	–	45.8%).	Reasons	for	consultation	
included	prophylaxis	(513	pts.	–	62.6%),	changes	(ie.	warts)	(78	
pts.	–	9.5%),	suspicion	of	HPV	in	their	partner	(46	pts.	–	5.6%),	
changes	 in	 their	 partner	 (cancer)	 or	HPV	 infection	 (160	 pts.	 –	
19.5%),	 and	 follow-up	 after	 HPV	 infection	 (23	 pts.	 –	 2.8%).	
Logistic	regression	analysis	and	Chi-square	test	were	calculated	
using	pack	SPSS	ver.17.	
We	 searched	 for	 the	 relationship	 between	 the	 reason	 of	
consultation	and	the	discovery	of	HPV,	its	types,	and	number	of	
genotypes.	We	considered	p<0.05	as	statistically	significant.
Results
Primarily	 asymptomatic	men	were	 examined	 for	multiple-
type	HPV.	Polymerase	chain	reaction	(PCR)	was	used	to	estimate	
the	amount	of	HPV	in	 the	materials	 sampled	 from	 the	urethral	
meatus,	 navicular	 fossa,	 and	 pathological	 foci.	 Types	 16,	 18,	
31,	33,	35,	39,	45,	51,	58,	59,	and	66	were	considered	high-risk	
oncogenic,	while	types	6,	10,	11,	13,	30,	34,	40,	42,	53,	61,	62,	
and	68	were	considered	low-risk	or	nononcogenic.
 Streszczenie 
Wprowadzenie: Oceniono, że zakażenia wirusem brodawczaka ludzkiego są przenoszo-ne drogą płciową. 
Występowanie ich jest porównywalne u obojga płci, ale u mężczyzn pozostaje w znacznej mierze niepoznane.
Cel pracy: Istnieje potrzeba opracowania strategii prewencji i celem naszych badań było ustalenie występowania 
zakażeń HPV i ich typów u mężczyzn w Polsce.
Materiał i metody: W wieloośrodkowych badaniach prewencyjnych przebadano 826 (100%) nieobrzezanych 
i aktywnych seksualnie mężczyzn w wieku od 25 do 69 lat. Poza rutynowymi badaniami klinicznymi wykonywano 
penisoskopię. DNA HPV wykrywano w wymazach metodą Hybrid Capture (HC2) oraz w materiale biopsyjnym 
metodą reakcji łańcuchowej polimerazy (PCR).
Wyniki: Wykryto 23 typy HPV łącznie z onkogennymi jedenastoma wysokiego ryzyka u 53 (6,4%) oraz u 65 
(7,87%) mężczyzn onkogennymi i nieonkogennymi – łącznie u 118 (14,3%) a także 12 różnorodnych niskiego 
ryzyka nieonkogennych typów HPV u 248 (30%) mężczyzn. W obrębie prącia HPV DNA wykryto u 26,8% badanych. 
Pośród 53 (6,4%) mężczyzn, poza różnymi typami onkogennymi, samych HPV 16 wykryto u 17 (2,1%). Wykryte 
w obrębie prącia HPV DNA nie zależało od wieku badanego. Nasze badania również sugerują mniejszą częstotliwość 
zakażeń HPV u stosujących kondomy i mających mniej partnerek seksualnych. U mężczyzn mających w przeszłości 
powyżej 10 partnerek rosła częstotliwość wykrywania HPV DNA.
Wnioski: Uzyskane wyniki przedstawiają wysoką liczbę zakażeń HPV mężczyzn w  badanej populacji w Polsce, 
a to może posłużyć do przyszłych badań dynamiki przenoszenia zakażeń HPV. 
 Słowa kluczowe: wirus brodawczaka ludzkiego / HPV / zakażenia genitalne /
       /rak szyjki macicy /choroby przenoszone drogą płciową /
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Cases	 of	 mixed	 oncogenic/nonocogenic	 multi	 type	 HPV	
infection	 occurred	 in	 the	 following	 combinations:	 6+16,	 6+31,	
6+33,	 6+51,	 6+53+59,	 10+16,	 13+51,	 16+30,	 16+53,	 16+61,	
31+30,	31+42,	31+61,	39+62,	51+61,	53+59,	and	58+62;	while	
multi	 type	 strictly	 oncogenic	 cases	 occurred	 in	 the	 following	
combinations:	16+31,	16+58,	31+35,	and	31+59.	
Overall	366	(44.3%)	men	had	multiple	HPV:	high-risk	was	
detected	 118	 (14.3%),	 and	 low-risk	 type	 HPV	 was	 found	 in	
248(30%).	Multi-type	oncogenic	HPV	infection	was	detected	in	
53	(6.4%)	of	men	and	only	17	(2.1%)	had	infection	with	single	
oncogenic	HPV16.	Both	oncological	and	non-oncological	types	
were	detected	in	65	cases	(7.87%).
The	results	of	regression	analysis	include	a	95%	confidence	
interval	(95%	CI)	for	 the	odds	ratio	(OR),	which	estimated	the	
association	 of	 the	 variables	 with	 the	 occurrence	 of	 HPV.	 The	
occurrence	of	HPV	infection	in	men	was	significantly	associated	
with	 the	 number	 of	 female	 sexual	 partners	 over	 the	 last	 12	
months.	 While	 men	 who	 had	 more	 that	 three	 female	 sexual	
partners	 (OR:	 1.44,	 95%	 CI:	 1.17-1.77)	 in	 that	 same	 period	
suffered	 from	 greater	 occurrence	 of	 HPV	 infection	 than	 those	
with	less	than	three	partners	(OR:	0.79,	95%	CI:	0.67-0.92).	Also,	
the	occurrence	of	HPV	infection	was	greater	in	men	younger	than	
34	years	of	age	than	those	who	were	34	or	older	(OR:	1·08,	95%	
CI:0.92-1.26	and	OR:	0.90,	95%	CI:	0.73-1.11	respectively)	as	
well	 as	 in	 those	who	 did	 not	 use	 condoms	when	 compared	 to	
those	that	used	condoms	(OR:	1.40,	95%	CI:	1.14-1.72	and	OR:	
0.8,	 95%	CI:	 0.68-0.93	 respectively);	 however,	 the	 differences	
were	not	statistically	significant.	(Figure	1).
The	 occurrence	 of	 oncogenic	 HPV	 infection	 in	 men	 was	
significantly	higher	in	men	who	did	not	use	condoms	(OR:	1.82,	
95%	CI:	1.41-2.35)	when	compared	to	those	who	used	condoms	
(OR:	0.58,	95%	CI:	0.39-0.84).	While	men	who	had	more	 that	
three	 female	 sexual	 partners	 in	 the	 last	 12	months	 (OR:	 1.86,	
95%	CI:	 1.44-2.04)	 in	 that	 same	 period	 suffered	 from	 greater	
occurrence	 of	 HPV	 infection	 than	 those	 with	 less	 than	 three	
partners	(OR:	0.57,	95%	CI:	0.39-0.83).	
Although	 regression	 analysis	 did	 not	 reveal	 a	 relationship	
between	 condom	 use	 and	 the	 prevalence	 of	 oncogenic	 HPV,	
the	 Chi-square	 test	 showed	 a	 relationship	 regardless	 of	 age	
(p>0.0001).	 The	 failure	 of	 regression	 analysis	 to	 confirm	 the	
relationship	of	condom	use	may	result	from	a	common	variance	
of	this	factor	with	the	number	of	partners	in	the	past	12	months.
The	 age	 of	 men	 was	 not	 associated	 with	 the	 occurrence	
of	 oncogenic	 HPV,	 despite	 the	 slightly	 greater	 occurrence	 of	
oncogenic	HPV	in	men	younger	than	34	years	of	age	(OR:	1.05,	
95%	CI:	 0.80-1.37)	when	compared	 to	 those	34	or	older	 (OR:	
0·94,	95%	CI:	0.66-1.33).
The	occurrence	of	nononcogenic	HPV	infection	in	men	was	
also	significantly	higher	in	men	who	had	more	than	three	partners	
in	 the	 last	 12	 months	 (OR:	 1.14,	 95%	 CI:	 0.86-1.52)	 when	
compared	to	those	with	less	than	three	partners	(OR:	0.92,	95%	
CI:	 0.77-1.10).	 Statistically	 insignificant	 results	 referred	 to	 the	
higher	prevalence	of	nononcogenic	HPV	in	men	below	34	years	
of	age	(OR:	1.01,	95%	CI:	0.82-1.24)	when	compared	to	men	34	
or	older	(OR:	0.98,	95%	CI:	0·77-1.26)	and	in	those	who	did	not	
use	condoms	(OR:	1.12,	95%	CI:	0.84-1.49)	when	compared	to	
those	who	did	(OR:	0.93,	95%	CI:	0.78-1.11).
The	 occurrence	 of	mixed	HPV	 infection	was	 significantly	
higher	among	men	with	more	 than	 three	sexual	partners	 in	 the	
past	12	months	(OR:	1.23,	95%	CI:	0.72-2.10)	when	compared	to	
men	with	fewer	partners	(OR:	0.88,	95%	CI:	0.59-1.29).	
A	marginally	higher	occurrence	of	mixed	HPV	also	occurred	
in	 men	 aged	 below	 34	 (OR:	 1.37,	 95%	 CI:	 1.04-1.80)	 when	
compared	to	med	aged	34	or	older	(OR:	0.56,	95%	CI:	0.26-1.21).	
The	use	of	condoms	was	not	significantly	associated	with	mixed	
HPV	despite	 the	 greater	 incidence	 among	men	using	 condoms	
(OR:	1.20,	95%	CI:	0.70-2.06)	when	compared	to	those	who	did	
not	use	condoms	(OR:	0.88,	95%	CI:	0.60-1.30).	
It	 should	 also	 be	 noted	 that	 multi-type	 HPV	 was	 not	
significantly	 associated	 with	 age,	 condom	 use,	 or	 number	 of	
partners	in	the	last	12	months.	(Figure	2).
Penile	HPV	DNA	detection	did	not	appear	to	be	associated	
with	 age.	 Our	 analyses	 also	 suggested	 a	 lower	 prevalence	 of	
HPV	infection	among	male	participants	who	reported	consistent	
condom	use,	and	fewer	female	sexual	partners.	In	men	having	a	
history	of	more	than	10	female	sexual	partners	over	their	lifetime,	
an	 increased	 likelihood	 of	 detecting	 HPV	DNA	was	 observed	
(data	not	shown).
Figure 1. Odds ratio (OR) of single and multi-genotype HPV infections as related to 
age, condom use, and number of sexual partners in the last 12 months.
Figure 2. Odds ratio (OR) of oncogenic, nononcogenic, and mixed HPV infections 
as related to age, condom use, and number of sexual partners in the last 12 months.
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Discussion
HPV	prevalence	 and	 incidence	 is	 similar	 among	men	 and	
women	[8].	HPV	causes	infections	in	the	stratified	epithelium	of	
the	skin	or	mucous	membranes.	Many	types	of	HPV	are	sexually	
transmitted	 and	 infect	 the	 anogenital	 region.	 Some	HPV	 types	
cause	genital	warts,	while	persistent	 infections	with	other	HPV	
types	can	lead	to	precancerous	lesions	and	invasive	cancer	[9,	10].	
The	common	sexually	transmitted	infection	of	HPV	is	the	most	
important	 risk	 factor	 for	cervical	cancer.	Little	 is	known	about	
multiple-type	 HPV	 prevalence	 and	 associated	 factors	 in	 men,	
although	men	contributed	the	main	source	of	infection	[11].	HPV	
infection	of	the	uterine	cervix	is	known	to	be	a	very	important	risk	
factor	 for	 the	 development	 of	 cervical	 intraepithelial	 neoplasia	
(CIN)	 and	 invasive	 cancer.	 Infection	 of	 HPV,	 even	 though	 it	
affects	both	sexual	partners,	is	presently	most	often	investigated	
in	females;	however,	 the	male	plays	one	of	 the	most	 important	
roles	in	the	causation	of	cervical	cancer	[12].	
Many	studies	have	confirmed	 the	 relationship	between	 the	
presence	of	HPV	 infection	 in	 the	male	genitals	and	 the	 risk	of	
uterine	cervix	cancer	in	their	partners.	In	many	male	studies	only	
subclinical	 infections	were	detected	[12].	Detection	of	multiple	
HPV	 types	 in	 our	 study	 of	 primarily	 asymptomatic	 men	 was	
common,	 particularly	 at	 the	 urethral	 meatus	 (navicular	 fossa)	
or	any	other	external	genital	 sites.	Penile	HPV	prevalence	was	
approximately	39-89%	among	men	in	Poland.	This	data	will	help	
inform	studies	on	HPV	transmission	dynamics.	 In	our	opinion,	
urethral	 cytology	 should	 be	 routinely	 used	 in	 association	with	
peniscopy	as	a	screening	test	for	the	detection	of	HPV	infection	
in	men	who	are	partners	of	women	with	HPV-induced	lesions.
Studies	performed	in	Mexico,	Brazil,	and	the	USA	showed	
that	half	of	adult	men	may	be	infected	with	the	HPV	and	also	that	
about	6%	of	men	are	newly	infected	with	HPV	16	each	year.	The	
study	was	comprised	of	1159	men	who	were	HIV	negative	and	
reported	no	history	of	cancer,	aged	18	to	70	years.	Moreover,	men	
who	had	50	or	more	female	partners	were	at	2.4	times	increased	
risk	for	oncogenic	HPV	infections	versus	 those	with	one	or	no	
partners.	 The	 risk	 for	 men	 who	 had	 at	 least	 one	 male	 sexual	
partner	was	2.6	times	higher	than	a	man	with	no	recent	partners.	
To	this	point,	HPV	vaccination	has	been	uncommon	in	males.	It	
should	be	noted	that	as	more	diseases	are	prevented	through	the	
vaccination	of	males;	however,	routine	vaccination	for	both	sexes	
should	prove	to	be	more	cost	effective	[2].
Recently	it	has	been	established	that	the	HPV	vaccines	elicit	
robust	 antibody	 responses	 in	men	 and	 are	 safe	 and	 efficacious	
against	HPV	infection	and	external	genital	lesions	among	young	
men	[13,	14].	The	vaccines	against	types	16	and	18	could	prevent	
two-thirds	 of	 invasive	 anal	 cancers	 and	 one-third	 of	 penile	
squamous	 cell	 carcinomas	 [15,	 16],	 and	 the	 quadrivalent	HPV	
vaccine	would	prevent	the	majority	of	genital	warts	cases.
The	 clinical	 significance	 of	 multiple	 HPV	 infections	
(with	 both	 high-risk	 and	 low-risk	 types)	 is	 unknown,	 but	 it	 is	
possible	 that	non-oncogenic	HPV	types	contribute	 to	enhanced	
keratinocyte	 proliferation	 resulting	 in	 facilitation	 of	 oncogenic	
HPV	 infection	 [17].	HPV	 infections	with	more	 than	 one	HPV	
type	were	considered	as	high-risk	if	any	HPV	type	detected	was	
high-risk	[18].	
In	summation,	it	is	estimated	that	half	of	sexually	active	males	
and	females	will	become	infected	with	HPV	during	their	lifetime	
[19].	Most	individuals	infected	with	HPV	are	asymptomatic,	but	
4%	of	sexually	active	males	in	the	USA	report	having	a	history	
of	genital	warts,	and	persistent	infection	with	HPV	among	males	
may	lead	to	penile,	anal,	and	head	&	neck	cancers	[20,	21,	22].	
The	 HPV	 vaccine	 protects	 males	 and	 females	 against	 cancers	
caused	by	 types	16	and	18	and	genital	warts	caused	by	 type	6	
and	11	[23].	In	addition,	vaccinating	males	will	indirectly	assist	
in	 the	 prevention	 of	HPV-related	 diseases	 (ie.	 cervical	 cancer)	
among	females	[22].	The	clinical	significance	of	multiple	HPV	
infections	(with	both	high-risk	and	low-risk	types)	is	unknown,	
but	 it	 is	 possible	 that	 non-oncogenic	 HPV	 types	 contribute	 to	
enhanced	 keratinocyte	 proliferation	 resulting	 in	 facilitation	 of	
oncogenic	HPV	infection	[22,	24].
Conclusion
Since	 men	 may	 transmit	 HPV	 infection	 to	 their	 female	
sexual	partners,	cervical	cancer	prevention	strategies	are	needed	
and	should	include	the	use	of	prophylactic	HPV	vaccines.		
The	data	obtained	from	our	study	showed	that	genital	HPV	
infection	is	common	in	the	Polish	population	of	men	and	will	be	
helpful	for	future	studies	on	HPV	transmission	dynamics.
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